FDA Seeks Public Input on Regulatory Framework for Generative AI Medical Devices

The U.S. Food and Drug Administration (FDA) has launched a formal inquiry into the regulation of generative AI (GenAI)-enabled medical devices to ensure patient safety while accelerating innovation. On August 18, 2026, the agency issued a discussion paper soliciting critical feedback from clinicians, researchers, and manufacturers on how to oversee this emerging class of technology.

The FDA is specifically requesting input on three primary pillars: risk assessment, premarket evaluation, and postmarket monitoring. To facilitate this, the agency has opened public docket FDA-2026-N-7874 on Regulations.gov, with a submission deadline set for October 19, 2026. This initiative is led by the Digital Health Center of Excellence (DHCoE) within the FDA's Center for Devices and Radiological Health (CDRH).

The Shift Toward Specialized Oversight

This regulatory push aligns with the Trump Administration's priority to harness artificial intelligence to speed up the delivery of medical products. The FDA is moving toward a specialized approach for GenAI because these tools introduce unique risks that differ from traditional software or standard AI-enabled devices. Unlike previous iterations of medical software, generative AI is often non-deterministic, meaning it can produce different outputs for the same input, necessitating a new branch of regulatory science.

Acting FDA Commissioner Kyle Diamantas, J.D., emphasized the importance of the move, stating that "artificial intelligence is transforming medicine, and the United States must lead in shaping how this technology is developed and used safely and responsibly."

New Validation Models

To address these challenges, the FDA is proposing a "competency assessment" model for premarket evaluation. This approach mirrors the way physicians are trained and certified, shifting the focus toward the device's ability to perform specific tasks reliably. Additionally, the agency is suggesting a two-axis risk assessment framework to categorize the potential impact and probability of failure for GenAI tools.

If adopted, these models could establish a global benchmark for how foundation models and agentic AI are validated before they reach the clinic. FDA Center for Devices and Radiological Health Director Michelle Tarver, M.D., Ph.D., noted that "patients and clinicians deserve a regulatory approach that keeps pace with the rapid innovation of digital health technologies."

Next Steps for the Industry

The industry now has until mid-October to shape the final framework. The primary focus for stakeholders will be determining how the proposed two-axis framework handles the inherent unpredictability of large language models in high-stakes medical environments. The FDA's final guidance will likely determine the speed at which GenAI-enabled diagnostic and treatment tools can move from the lab to the bedside.